{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:48:07Z","timestamp":1793785687337,"version":"4.6.1"},"reference-count":69,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic graft-versus-host disease (GVHD) is 1 of the major complications after allogeneic hematopoietic cell transplantation (allo-HCT). Although various risk factors for chronic GVHD have been reported, limited data are available regarding the impact of acute GVHD on chronic GVHD. We examined the association between acute and chronic GVHD using a Japanese registry data set. The landmark point was set at day 100 after allo-HCT, and patients who died or relapsed before the landmark point were excluded. In total, 14\u2009618 and\u00a06135 patients who underwent allo-HCT with bone marrow or peripheral blood (BM\/PB) and with umbilical cord blood (UCB), respectively, were analyzed. In the BM\/PB cohort, the risk for chronic GVHD that requires systemic steroids increased with each increase in acute GVHD grade from 0 to 2 (grade 0 vs 1 [hazard ratio (HR), 1.32; 95% confidence interval (CI), 1.19-1.46; P\u00a0&amp;lt; .001]; grade 1 vs 2 [HR, 1.41; 95%\u00a0CI, 1.28-1.56; P\u00a0&amp;lt; .001]), but the risk was similar between acute GVHD grade 2 and grade 3 to 4 (HR, 1.02; 95%\u00a0CI, 0.91-1.15; P\u00a0=\u00a01.0). These findings were confirmed in the UCB cohort. We further observed that the risk for severe chronic GVHD increased with each increment in the grade of acute GVHD, even between acute GVHD grade 2 and grade 3 to (grade 2 vs 3-4: HR, 1.70; 95%\u00a0CI, 1.12-2.58; P\u00a0=\u00a0.025). In conclusion, the preceding profiles of acute GVHD should help to stratify the risk for chronic GVHD and its severity, which might be useful for the development of risk-adopted preemptive strategies for chronic GVHD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013442","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:11:07Z","timestamp":1720624267000},"page":"4250-4261","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Associations between acute and chronic graft-versus-host disease"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-7913","authenticated-orcid":false,"given":"Masaharu","family":"Tamaki","sequence":"first","affiliation":[{"name":"1Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"2Division of Emerging Medicine for Integrated Therapeutics, Center for Molecular Medicine, Jichi Medical University Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9340","authenticated-orcid":false,"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"3Division of Hematology\/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"4Department of Bone and Marrow Transplantation & Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-8189","authenticated-orcid":false,"given":"Kaoru","family":"Morita","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Jichi Medical University, Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-3179","authenticated-orcid":false,"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"7Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nishida","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ohigashi","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-990X","authenticated-orcid":false,"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Onizuka","sequence":"additional","affiliation":[{"name":"12Department of Hematology\/Oncology, Tokai University School of Medicine, Isehara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9104","authenticated-orcid":false,"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"14Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[{"name":"15Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7668-6083","authenticated-orcid":false,"given":"Fumihiko","family":"Ishimaru","sequence":"additional","affiliation":[{"name":"16Technical Department, Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan"},{"name":"5Division of Hematology, Jichi Medical University, Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"17Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"18Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan"},{"name":"19Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-8046","authenticated-orcid":false,"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[{"name":"20Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[{"name":"21Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"2","key":"2024082712354352600_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024082712354352600_bib2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2024082712354352600_bib3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41409-018-0340-0","article-title":"Ocular graft-versus-host disease after hematopoietic cell transplantation: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT","volume":"54","author":"Inamoto","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024082712354352600_bib4","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/cam4.5209","article-title":"Patient-reported symptom burden and impact on daily activities in chronic graft-versus-host disease","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"issue":"17","key":"2024082712354352600_bib5","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2024082712354352600_bib6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2024082712354352600_bib7","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2014.109611","article-title":"Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease","volume":"99","author":"Inamoto","year":"2014","journal-title":"Haematologica"},{"issue":"20","key":"2024082712354352600_bib8","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2024082712354352600_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2022.6624","article-title":"Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease","volume":"159","author":"Baumrin","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"2024082712354352600_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3324\/haematol.2018.192930","article-title":"Patient-reported outcomes and health status associated with chronic graft-versus-host disease","volume":"103","author":"Lee","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2024082712354352600_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2019.05.016","article-title":"Resolved versus active chronic graft-versus-host disease: impact on post-transplantation quality of life","volume":"25","author":"Kurosawa","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024082712354352600_bib12","doi-asserted-by":"crossref","first-page":"97.e1","DOI":"10.1016\/j.jtct.2023.10.010","article-title":"Severity of chronic graft-versus-host disease and late effects following allogeneic hematopoietic cell transplantation for adults with hematologic malignancy","volume":"30","author":"Lee","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2024082712354352600_bib13","doi-asserted-by":"crossref","first-page":"712.e1","DOI":"10.1016\/j.jtct.2022.07.014","article-title":"Association of chronic graft-versus-host disease with late effects following allogeneic hematopoietic cell transplantation for children with hematologic malignancy","volume":"28","author":"Lee","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024082712354352600_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bmt.2013.151","article-title":"Risk factors and organ involvement of chronic GVHD in Japan","volume":"49","author":"Kanda","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024082712354352600_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/bmt.2016.328","article-title":"Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant","volume":"52","author":"Watkins","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024082712354352600_bib16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024082712354352600_bib17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12032-018-1127-2","article-title":"Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting","volume":"35","author":"Afram","year":"2018","journal-title":"Med Oncol"},{"issue":"1","key":"2024082712354352600_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbmt.2015.09.008","article-title":"Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors","volume":"22","author":"Lazaryan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024082712354352600_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bbmt.2017.11.004","article-title":"Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: implications for prophylaxis","volume":"24","author":"Qayed","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024082712354352600_bib20","doi-asserted-by":"crossref","first-page":"571884","DOI":"10.3389\/fimmu.2020.571884","article-title":"\"Age related differences in the biology of chronic graft-versus-host disease after hematopoietic stem cell transplantation\"","volume":"11","author":"Cuvelier","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"2024082712354352600_bib21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024082712354352600_bib22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1182\/blood.2019000216","article-title":"Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria","volume":"134","author":"Cuvelier","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2024082712354352600_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","article-title":"Risk factors and outcome of chronic graft-versus-host disease after allogeneic stem cell transplantation-results from a single-center observational study","volume":"22","author":"Grube","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024082712354352600_bib24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bbmt.2020.05.001","article-title":"Risk factors for graft-versus-host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide","volume":"26","author":"Im","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024082712354352600_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.16182","article-title":"Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study","volume":"188","author":"Bazarbachi","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2024082712354352600_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.bmt.1701423","article-title":"Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis","volume":"22","author":"Carlens","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2024082712354352600_bib27","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2014-11-613323","article-title":"Allogeneic HY antibodies detected 3\u00a0months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans","volume":"125","author":"Nakasone","year":"2015","journal-title":"Blood"},{"issue":"29","key":"2024082712354352600_bib28","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024082712354352600_bib29","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"2024082712354352600_bib30","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024082712354352600_bib31","doi-asserted-by":"crossref","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024082712354352600_bib32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/bmt.2016.265","article-title":"GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes","volume":"52","author":"Chen","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024082712354352600_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"2024082712354352600_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"issue":"6","key":"2024082712354352600_bib35","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024082712354352600_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024082712354352600_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2024082712354352600_bib38","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2024082712354352600_bib39","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2024082712354352600_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024082712354352600_bib41","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024082712354352600_bib42","first-page":"143","article-title":"Patient-reported treatment response in chronic graft-versus-host disease","volume":"109","author":"Im","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2024082712354352600_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024082712354352600_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"3","key":"2024082712354352600_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2024082712354352600_bib46","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024082712354352600_bib47","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.1182\/blood-2010-12-323824","article-title":"Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis","volume":"117","author":"Arora","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2024082712354352600_bib48","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/leu.2012.292","article-title":"Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study","volume":"27","author":"Arora","year":"2013","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2024082712354352600_bib49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2023-182438","article-title":"Machine learning validates risk biomarkers of chronic graft-versus-host disease in 936 patients from BMT CTN 0201 & 1202 cohorts","volume":"142","author":"Martens","year":"2023","journal-title":"Blood"},{"issue":"22","key":"2024082712354352600_bib50","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood.2021012431","article-title":"Nonclassical manifestations of acute GVHD","volume":"138","author":"Zeiser","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2024082712354352600_bib51","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1182\/blood-2006-07-034157","article-title":"Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation","volume":"109","author":"Hauri-Hohl","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2024082712354352600_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood.V96.1.347","article-title":"Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells","volume":"96","author":"Krenger","year":"2000","journal-title":"Blood"},{"issue":"17","key":"2024082712354352600_bib53","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2014-08-597245","article-title":"Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD","volume":"125","author":"Dertschnig","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2024082712354352600_bib54","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/blood-2006-08-042853","article-title":"Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease","volume":"109","author":"Sakoda","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2024082712354352600_bib55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2214\/ajr.149.2.269","article-title":"Thymic atrophy and regrowth in response to chemotherapy: CT evaluation","volume":"149","author":"Choyke","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"2024082712354352600_bib56","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2302892","article-title":"Health consequences of thymus removal in adults","volume":"389","author":"Kooshesh","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024082712354352600_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.2019003369","article-title":"The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD","volume":"136","author":"Markey","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024082712354352600_bib58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.2019000950","article-title":"Microbiome-intestine cross talk during acute graft-versus-host disease","volume":"136","author":"Rafei","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2024082712354352600_bib59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood.2023019875","article-title":"Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT","volume":"142","author":"Senjo","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2024082712354352600_bib60","doi-asserted-by":"crossref","first-page":"e170125","DOI":"10.1172\/JCI170125","article-title":"Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD","volume":"134","author":"Wang","year":"2024","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2024082712354352600_bib61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood.2021013244","article-title":"Metabolomic identification of \u03b1-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease","volume":"139","author":"Subburaj","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2024082712354352600_bib62","doi-asserted-by":"crossref","first-page":"759.e1","DOI":"10.1016\/j.jtct.2021.06.006","article-title":"Relevance of plasma matrix metalloproteinase-9 for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation","volume":"27","author":"Inamoto","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"2024082712354352600_bib63","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1182\/bloodadvances.2021005930","article-title":"MicroRNA serum profiles and chronic graft-versus-host disease","volume":"6","author":"Reikvam","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2024082712354352600_bib64","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/bloodadvances.2020001485","article-title":"Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation","volume":"4","author":"Inamoto","year":"2020","journal-title":"Blood Adv"},{"issue":"22","key":"2024082712354352600_bib65","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.2015.65.9615","article-title":"Biomarker panel for chronic graft-versus-host disease","volume":"34","author":"Yu","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024082712354352600_bib66","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2017.04.019","article-title":"Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease","volume":"23","author":"Inamoto","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2024082712354352600_bib67","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/bloodadvances.2019000629","article-title":"Increased Mac-2 binding protein glycan isomer in patients at risk for late nonrelapse mortality after HSCT","volume":"3","author":"Akahoshi","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2024082712354352600_bib68","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbmt.2015.01.003","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 Biomarker Working Group Report","volume":"21","author":"Paczesny","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2024082712354352600_bib69","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4250\/2239654\/blooda_adv-2024-013442-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4250\/2239654\/blooda_adv-2024-013442-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T12:36:25Z","timestamp":1724762185000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4250\/516928\/Associations-between-acute-and-chronic-graft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":69,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013442","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}